四環醫藥(00460.HK):惠升生物開發的司美格魯肽注射液上市申請獲NMPA受理
格隆匯8月15日丨四環醫藥(00460.HK)公佈,集團旗下非全資附屬公司惠升生物製藥股份有限公司開發的司美格魯肽注射液上市申請獲得國家藥品監督管理局(NMPA)受理,用於改善成人2型糖尿病患者的血糖控制。此外,司美格魯肽注射液用於減重的適應症已完成III期臨牀入組,處於隨訪階段。
司美格魯肽注射液是一週注射一次的長效GLP-1受體激動劑(GLP-1RA),可通過啓動GLP-1受體,以葡萄糖濃度依賴的方式增強胰島素分泌,抑制胰高血糖素分泌,並能夠延緩胃排空,從而達到降低血糖的作用;同時,司美格魯肽可降低食慾和減少食物攝入量,幫助患者減少熱量攝入,從而達到降低體重的作用。
糖尿病領域爲惠升生物重點佈局領域,本次司美格魯肽注射液上市申請獲國家藥監局受理,是該款藥物研發進程中的又一重要進展,將有助於進一步提升集團和惠升生物在糖尿病治療領域的核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.